Patents by Inventor Joseph Shiloach
Joseph Shiloach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160319277Abstract: The invention provides a method of increasing protein production in a cell by contacting the cell with miRNA, siRNA or a combination thereof, or increasing protein production by genome editing methodologies to silence or inhibit gene expression. A screening method for obtaining such miRNA or siRNA species is also provided, as well as identification of target genes for genome editing.Type: ApplicationFiled: January 28, 2016Publication date: November 3, 2016Inventors: Joseph Shiloach, Michael J. Betenbaugh, Scott E. Martin, Su Xiao, Yu-Chi Chen
-
Patent number: 8481048Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.Type: GrantFiled: October 20, 2009Date of Patent: July 9, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of HealthInventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
-
Patent number: 8394387Abstract: The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: GrantFiled: July 31, 2007Date of Patent: March 12, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Stephen H. Leppla, Mary Jo Rosovitz, John B. Robbins, Rachel Schneerson, S. Dana Hsu, Joseph Shiloach, Delia M. Ramirez
-
Publication number: 20130058967Abstract: The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: ApplicationFiled: July 31, 2007Publication date: March 7, 2013Inventors: Stephen H. Leppla, Mary Jo Rosovitz, John B. Robbins, Rachel Schneerson, S. Dana Hsu, Joseph Shiloach, Delia M. Ramirez
-
Patent number: 8202520Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: GrantFiled: May 28, 2010Date of Patent: June 19, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
-
Publication number: 20120039939Abstract: The present invention features methods of producing immunogenic compositions and viruses, methods of treating and preventing viral infection, and methods of producing an immune response using cells that express a polypeptide selected from the group consisting of: cdk13, siat7e, Iama4, cox15, egr1, gas6, map3k9, and gap43, and a virus.Type: ApplicationFiled: April 10, 2009Publication date: February 16, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Joseph Shiloach, Michael Betenbaugh, Pratik Jaluria, Chia Chu
-
Publication number: 20110200987Abstract: The invention generally provides compositions and methods for modulating cell properties and enhancing recombinant protein yields. In particular, the compositions and methods provide for cells having altered growth characteristics, including altered adhesion, rate of proliferation, growth to particular cell density, and recombinant protein expression level.Type: ApplicationFiled: August 24, 2007Publication date: August 18, 2011Applicants: Government of the United States of America, as represented by the Secretary, Department of Health, The John Hopkins UniversityInventors: Joseph Shiloach, Pratik Jaluria, Michael Betenbaugh
-
Patent number: 7803386Abstract: Immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacilli are provided that include immunogenic conjugates of a poly-?-glutamic acid (?PGA) polypeptide of B. anthracis, or of another Bacillus that expresses a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against B. anthracis, or against another Bacillus, in mammalian hosts to which the conjugates are administered.Type: GrantFiled: June 4, 2004Date of Patent: September 28, 2010Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Rachel Schneerson, Stephen Leppla, John B. Robbins, Joseph Shiloach, Joanna Kubler-Kielb, Darrell Liu, Fathy Majadly
-
Publication number: 20100239601Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: ApplicationFiled: May 28, 2010Publication date: September 23, 2010Inventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
-
Patent number: 7763451Abstract: The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: GrantFiled: November 8, 2002Date of Patent: July 27, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Joseph Shiloach, Stephen H. Leppla, Delia M. Ramirez, Rachel Schneerson, John B. Robbins, S. Dana Hsu, Mary Jo Rosovitz
-
Patent number: 7754227Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: GrantFiled: March 20, 2007Date of Patent: July 13, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
-
Publication number: 20100040644Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.Type: ApplicationFiled: October 20, 2009Publication date: February 18, 2010Inventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
-
Patent number: 7625736Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazino-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.Type: GrantFiled: December 6, 2004Date of Patent: December 1, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
-
Publication number: 20070172501Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: ApplicationFiled: March 20, 2007Publication date: July 26, 2007Inventors: Zuzana Kossaczka, Shousun Szu, John Robbins, Rachel Schneerson, Joseph Shiloach
-
Publication number: 20060134143Abstract: Immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacilli are provided that include immunogenic conjugates of a poly-?-glutamic acid (?PGA) polypeptide of B. anthracis, or of another Bacillus that expresses a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against B. anthracis, or against another Bacillus, in mammalian hosts to which the conjugates are administered.Type: ApplicationFiled: June 4, 2004Publication date: June 22, 2006Inventors: Rachel Schneerson, Stephen Leppla, John Robbins, Joseph Shiloach, Joanna Kubler-Kielb, Darrell Liu, Fathy Majadly
-
Publication number: 20040223973Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againt S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: ApplicationFiled: June 10, 2004Publication date: November 11, 2004Applicant: The Gov. of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
-
Publication number: 20040076638Abstract: The invention relates to improved methods of producing and recovering B. anthracisprotective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: ApplicationFiled: November 8, 2002Publication date: April 22, 2004Inventors: Joseph Shiloach, Stephen H. Leppla, Delia M. Ramirez, Rachel Schneerson, John B. Robbins
-
Patent number: 5539877Abstract: A limited multi-fault system and method manages error recovery in a local area network system. The system includes a data structure which store related error events, diagnostic problems and causes. In addition, a method of managing error events in real time and identifying causes and recommending actions is provided. A knowledge base is used to determine the causes and recommended actions for the problem.Type: GrantFiled: June 27, 1994Date of Patent: July 23, 1996Assignee: International Business Machine CorporationInventors: Alex Winokur, Joseph Shiloach, Amnon Ribak, Yuangeng Huang
-
Patent number: 5483637Abstract: An expert based system for managing error events in a local area network (LAN) includes an inference engine and a knowledge base storing data defining a plurality of causal relationships. Each of the causal relationships associates an error message with a cause, at least one implied relationship, and at least one trigger relationship. The inference engine accesses said knowledge base in response to a receiver error message to identify the error message and retrieve from the knowledge base its possible causes. The received error message is compared with other already received error messages to filter out repeated error messages. Already received error messages are examined to determine whether a triggering error message has arrived and, if so, the received error is discarded.Type: GrantFiled: June 27, 1994Date of Patent: January 9, 1996Assignee: International Business Machines CorporationInventors: Alex Winokur, Joseph Shiloach, Amnon Ribak, Yuangene Huang
-
Patent number: 5338670Abstract: A fermentation level cultivation of Bordetella pertussis bacteria on commercial scale is described. The critical factors in large scale cultivation of the bacteria are the presence of an antifoam agent and maintaining proper oxygen level and iron content in the culture medium. Pertussis toxin produced by the bacteria parallels the rate of growth of the bacteria.Type: GrantFiled: December 11, 1992Date of Patent: August 16, 1994Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Ronald D. Sekura, Yan-Ling Zhang, Joseph Shiloach